Time-dependent inhibition of CYP3A4 by gallic acid in human liver microsomes and recombinant systems

Xenobiotica

Volumn 45, Issue 3, 2015, Pages 213-217

  Pu, Qiang Hong ^a   Shi, Liang ^a   Yu, Chao ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

6 hydroxylase; CYP3A4; Gallic acid; Testosterone; Time dependent inhibition

Indexed keywords

CYTOCHROME P450 3A4; GALLIC ACID; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RECOMBINANT PROTEIN; TESTOSTERONE;

ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; LIVER MICROSOME; STEROID HYDROXYLATION; TIME; DRUG EFFECTS; ENZYMOLOGY; HYDROXYLATION; METABOLISM;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INHIBITORS; GALLIC ACID; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; NADP; RECOMBINANT PROTEINS; TESTOSTERONE; TIME FACTORS;

EID: 84924069925     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.973470     Document Type: Article

References (28)

1. Cartron E, Fouret G, Carbonneau MA, et al. (2003). Red-wine beneficial long-term effect on lipids but not on antioxidant characteristics in plasma in a study comparing three types of wine-description of two O-methylated deriva tives of gallic acid in humans. Free Radic Res 37: 1021-35.
2. Crozier A, Jaganath IB, Clifford MN. (2009). Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26: 1001-43.
3. Feng S, He X. (2013). Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity. Curr Drug Metab 14: 921-45.
4. Fujita K. 2004 Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20 195-217.
5. Honig PK, Wortham DC, Zamani K, et al. (1993). Terfenadineketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-8.
6. Jin Y, Wang YH, Miao J, et al. (2007). Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 82:579-85
7. Kadono K, Koakutsu A, Naritomi Y, et al. (2014). Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method. Xenobiotica 44:511-21.
8. Kamel A, Harriman S. (2013). Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI). Drug Discov Today Technol 10:e177-89.
9. Kitz R, Wilson IB. (1962). Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-9.
10. Lamba JK, Lin YS, Schuetz EG, Thummel KE. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-94.
11. Li Z, Wang K, Zheng J, et al. (2014). Interactions of the active components of Punica granatum (pomegranate) with the essential renal and hepatic huma n Solute Carrier transporters. Pharm Biol 1-8 [Epub ahead of print]. doi:10.3109/13880209.2014.900809.
12. Lin JH, Lu AY. (1998). Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35: 361-90.
13. Manach C, Williamson G, Morand C, et al. (2005). Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S-42S.
14. McConn 2nd DJ, Lin YS, Allen K, et al. (2004). Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083-91.
15. Mouly SJ, Matheny C, Paine MF, et al. (2005). Variation in oral clearance of saquinavir is predicted by CYP3A51 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 78:605-18.
16. Perloff ES, Mason AK, Dehal SS, et al. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 39:99-112.
17. Roberts AT, Martin CK, Liu Z, et al. (2007). The safety and efficacy of a dietary herbal supplement and gallic acid for weight loss. J Med Food 10:184-8.
18. Shahrzad S, Aoyagi K, Wi nter A, et al. (2001). Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. J Nutr 131:1207-10.
19. Shi L, Zhang YD, Wang EH, et al. (2014). Inhibitory effect of gallic acid and its oxidation products on CYP3A in rat liver microsomes. J Third Military Medical University 36:130-4.
20. Stupans I, Stretch G, Hayball P. (2000). Olive oil phenols inhibit human hepatic microsomal activity. J Nutr 130:2367-70.
21. Stupans L, Tan HW, Kirlich A, et al. (2002). Inhibition of CYP3Amediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. J Pharm Pharmacol 54:269-75.
22. Tapaninen T, Neuvonen PJ, Niemi M. (2010). Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 66:497-502.
23. Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 38:389-430.
24. Verma S, Singh A, Mishra A. (2013). Gallic acid: molecular rival of cancer. Environ Toxicol Pharmacol 35: 473-85.
25. Wang L,Sweet DH. 2012). Potential for food-drug interactions by dietary phenolic acids on human organic anion transporters 1 (SLC22A6) 3 (SL C22A8), and 4 (SLC22A11). Biochem Pharmacol 84 1088-95.
26. Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30: 1311-9.
27. Yun CH, Okerholm RA, Guengerich FP. (1993). Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-d ealkylation and C-hydroxylation. Drug Metab Dispos 21:403-9.
28. Zhou S, Yung Chan S, Cher Goh B, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304.